Cogent Biosciences (COGT) Income towards Parent Company (2017 - 2026)

Cogent Biosciences (COGT) has reported Income towards Parent Company for 10 consecutive years, with -$111.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Income towards Parent Company fell 54.48% year-over-year to -$111.2 million; the TTM figure through Mar 2026 stood at -$382.5 million (down 41.15% YoY), while the FY2025 annual figure was -$1.1 billion, down 126.83% from the prior year.
• Income towards Parent Company slipped to -$111.2 million in Q1 2026 per COGT's latest filing, from -$110.1 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$35.9 million in Q1 2022 and bottomed at -$111.2 million in Q1 2026.
• Historically, Income towards Parent Company has averaged -$66.1 million across 5 years, with a median of -$62.8 million in 2024.
• Annual changes were most pronounced in 2022 — Income towards Parent Company sank 243.33% — and 2023, when it soared 36.61%.
• Cogent Biosciences' Income towards Parent Company stood at -$40.0 million in 2022, then slumped by 47.54% to -$59.0 million in 2023, then fell by 1.64% to -$60.0 million in 2024, then sank by 83.56% to -$110.1 million in 2025, then fell by 1.04% to -$111.2 million in 2026.
• Business Quant data shows COGT's Income towards Parent Company at -$111.2 million in Q1 2026, -$110.1 million in Q4 2025, and -$85.2 million in Q3 2025.